We are pleased to announce that patient dosing has begun in SHAPE, a Phase 2 #ClinicalTrial of ATH-1017 for the treatment of #Parkinsons disease dementia and #dementia with Lewy bodies.
Learn more: https://t.co/xDOMP1ujbT
Learn more about our LIFT-AD #ClinicalTrial evaluating ATH-1017 in patients with mild to moderate #Alzheimers, from study investigator Dr. Shishuka Malhotra.
Read in @CantonRepdotcom: https://t.co/1T6132U4gm
Portland #Alzheimers patient Sara and her son spoke with @KOINnews about the hope her family has found through #ClinicalTrial participation. We applaud Sara and her family's courage in sharing her story.
See the full story: https://t.co/KDRiDId8IY
For anyone impacted by #Alzheimer’s disease, check out our novel regenerative approach with the potential to boost neuronal health!
https://t.co/5mZ3GRX4Lp to learn more.
Do you or someone you know have mild to moderate #Alzheimer’s disease?
Participate in a research trial like ACT-AD, a 26-week study to evaluate treatment effects of ATH-1017.
For more information and study locations: https://t.co/dE1BlbSXLr
#Alzheimers#ClinicalTrial
Athira Pharma initiates patient dosing in LIFT-AD, a Phase 2/3 #ClinicalTrial for investigational drug ATH-1017 to treat mild-to-moderate #Alzheimers. https://t.co/UN13sw00cC
Help us win #geekwireawards for Health Innovation of the Year! Please cast one or multiple votes! Excited to be among this year’s finalists. Thank you @geekwire for the recognition! @leenkawas https://t.co/U068CgHhii
@Tesla worst Seattle/Bellevue customer experience and Tesla not honoring price drop from recent May price release. Anyone else have bad experiences? Wasted 2 hours at scheduled delivery time and did not walk away with the model S sitting in front of me at the lot
Help us WIN the @geekwire awards!
Follow the link, vote for each category, and make sure to select LEEN KAWAS and M3BIOTECHNOLOGY for the two categories we are in! Don’t forget to retweet and share! #endalz@leenkawas https://t.co/STjRicu3KJ
M3 Biotechnology begins testing of its novel therapy NDX-1017 in individuals with Alzheimer’s disease or mild cognitive impairment. Recruitment underway in the United States and France:
https://t.co/xx6wtPM4lf @leenkawas#Alzheimers#clinicaltrials#ENDALZ